My HPRA: Register

Important Safety Information from Marketing Authorisation Holders of products containing 5-Fluorouracil (i.v.), capecitabine and tegafur as approved by the HPRA

Notice type: 3rd Party Publications

Date: 04/06/2020

   

Problem Or Issue:
Important Safety Information from Marketing Authorisation Holders of products containing 5-Fluorouracil (i.v.), capecitabine and tegafur : Pre-treatment testing to identify DPD-deficient patients at increased risk of severe toxicity 


Important Safety Information from Marketing Authorisation Holders of products containing 5-Fluorouracil (i.v.), capecitabine and tegafur as approved by the HPRA

« Back